Division of Hematology and Department of Medicine, University Hospital Center Zagreb and School of Medicine University of Zagreb, Kispaticeva 12, 10 000 Zagreb, Croatia.
Pathol Oncol Res. 2011 Jun;17(2):243-7. doi: 10.1007/s12253-010-9304-4. Epub 2010 Sep 18.
Survivin is an inhibitor of apoptosis whose expression may be associated with inferior outcome in patients with diffuse large B-cell lymphoma (DLBCL) treated without rituximab. Caspase-3 is the final caspase of the apoptotic cascade and its pattern of expression may also be related to patients' outcome. In this study we investigated immunohistochemical expression of survivin and caspase-3 (CPP32) in 57 patients with DLBCL treated with rituximab and CHOP (R-CHOP). According to previously published criteria, we separately analyzed correlation of different types of survivin expression with patients' outcome. Nuclear survivin was expressed in only 26% of cases, cytoplasmic survivin was expressed in 81% of cases while application of immunoreactivity scoring system yielded 58% of survivin positive cases. Caspase-3 was expressed in 77% of cases. There were no significant correlations between any type of survivin expression and response to treatment or survival of the patients. The expression of caspase-3 was also not associated with patients' outcome. We conclude that survivin and caspase-3 have no significant prognostic significance in patients with DLBCL treated with R-CHOP.
存活素是凋亡抑制剂，其表达可能与未经利妥昔单抗治疗的弥漫性大 B 细胞淋巴瘤（DLBCL）患者的预后不良有关。半胱氨酸天冬氨酸蛋白酶-3（caspase-3）是凋亡级联反应的最后一种半胱氨酸蛋白酶，其表达模式也可能与患者的预后有关。在这项研究中，我们研究了 57 例接受利妥昔单抗和 CHOP（R-CHOP）治疗的 DLBCL 患者中存活素和半胱氨酸天冬氨酸蛋白酶-3（CPP32）的免疫组织化学表达。根据先前发表的标准，我们分别分析了不同类型的存活素表达与患者预后的相关性。核内存活素仅在 26%的病例中表达，细胞质内存活素在 81%的病例中表达，而免疫反应评分系统的应用使 58%的存活素阳性病例。半胱氨酸天冬氨酸蛋白酶-3在 77%的病例中表达。任何类型的存活素表达与治疗反应或患者的生存均无显著相关性。半胱氨酸天冬氨酸蛋白酶-3的表达也与患者的预后无关。我们的结论是，在接受 R-CHOP 治疗的 DLBCL 患者中，存活素和半胱氨酸天冬氨酸蛋白酶-3没有显著的预后意义。
